KeyNeurotek Pharmaceuticals Opens New Research Facilities in Leipzig

Press Release

KeyNeurotek Pharmaceuticals Opens New Research Facilities in Leipzig

Magdeburg, May 7, 2009 - KeyNeurotek Pharmaceuticals AG, a
biotechnology company focused on the development and marketing of
drugs against autoimmune diseases and degenerative disorders of the
central nervous system (CNS), today announced the opening of new
research facilities in Leipzig, Germany.

As part of the expansion of its business activities, KeyNeurotek
Pharma GmbH, a subsidiary of Magdeburg-based KeyNeurotek
Pharmaceuticals AG, has opened laboratory space and offices at
Leipzig's BIO CITY center in order to further expand its existing
network to research institutions in Leipzig. The research and
development activities in Leipzig will focus on several preclinical
projects as well as clinical development activities in the area of
urinary incontinence. At present, the company is preparing a
Phase-IIa proof-of-concept study of its KN203 product candidate, a
µ-opioid receptor agonist acting on bladder muscle contraction. The
clinical testing of KN203 is expected to start in 2009 immediately
after regulatory approval and will include 180 patients suffering
from urinary incontinence or an overactive bladder.

At the same time, all CNS-related development activities of
KeyNeurotek Pharmaceuticals AG will be expanded at the company's
Magdeburg site. KeyNeurotek's lead product KN38-7271, a dual
cannabinoid CB1/CB2 receptor agonist, is currently investigated in a
multinational Phase-IIa-study in comatose TBI patients to prove its
clinical safety and tolerability. Furthermore, KeyNeurotek
Pharmaceuticals is hoping for therapeutic efficacy signals. Study
results are expected this summer. KN38-7271 has been granted Orphan
Drug Designation by the European authorities.

Dr. Frank Striggow, CEO of KeyNeurotek Pharmaceuticals AG, said:
Setting up the business activities of KeyNeurotek Pharma GmbH in
Leipzig is an important milestone for KeyNeurotek. Moreover, the new
facilities reflect our strong relationships with the excellent
research cluster in the Middle Germany region."

About KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals, a privately held biotechnology company,
was founded in 2000 within the Magdeburg, Germany, region, one of the
leading centers of neuroscience in Europe.

The company pursues a number of drug candidates in various
preclinical and clinical stages. The most advanced compound,
KN38-7271, a cannabinoid receptor agonist, is in a Phase IIa trial in
comatose patients with traumatic brain injury. At present, there is
no targeted therapy for these patients.

KeyNeurotek Pharmaceuticals has unique functional and tissue-based
high throughput screening platforms for compatible ex vivo and in
vivo studies (TELOMICSTM). Based on its know-how, KeyNeurotek
develops innovative therapies for the treatment of various
neurodegenerative diseases of the central nervous system, such as
traumatic brain injury (TBI), stroke, Alzheimer's disease and urinary
incontinence/overactive bladder.
The company has built a strong network with renowned local and
international partners, including, among others, the Leibniz
Association, the Max Planck Society and Fraunhofer Society, Evotec,
Schwarz Pharma/UCB, Bayer Schering and Gruenenthal. KeyNeurotek
Pharmaceuticals has been awarded the Hugo-Junckers-Innovation Award
of the State of Sachsen-Anhalt in 2002 and 2004 and the Innovation
Award of the German Industry in 2006.

Contact:

Dr. Frank Striggow Dr. Ludger Weß

KeyNeurotek Pharmaceuticals AG akampion
ZENIT-Technologiepark Saseler Loge 6b
Leipziger Str. 44 D-22393 Hamburg
D-39120 Magdeburg
Tel. +49 40 88 16 59 64
Tel.: +49 391 6117 220 Mobile +49 160 96 65 29 58
Fax: +49 391 6117 221 ludger@akampion.com
frank.striggow@keyneurotek.de www.akampion.com
www.keyneurotek.de

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.